| 词条 | Dasatinib |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 458266659 | IUPAC_name = N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)- 1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate | image = Dasatinib.svg | width = 325 | image2 = Dasatinib-2GQG-ball-and-stick.png | width2 = 350 | tradename = Sprycel | Drugs.com = {{drugs.com|monograph|dasatinib}} | MedlinePlus = a607063 | licence_EU = yes | licence_US = Dasatinib | pregnancy_AU = D | pregnancy_US = D | legal_AU = S4 | legal_US = Rx-only | legal_status = ℞-only | routes_of_administration = By mouth (tablets) | bioavailability = | protein_bound = 96% | metabolism = Liver | elimination_half-life = 1.3 to 5 hours | excretion = Fecal (85%), kidney (4%) | IUPHAR_ligand = 5678 | CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 302962-49-8 | ATC_prefix = L01 | ATC_suffix = XE06 | PubChem = 3062316 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB01254 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 2323020 | UNII_Ref = {{fdacite|changed|FDA}} | UNII = X78UG0A0RN | KEGG_Ref = {{keggcite|changed|kegg}} | KEGG = D03658 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 49375 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1421 | C=22 | H=26 | Cl=1 | N=7 | O=2 | S=1 | molecular_weight = 488.01 g/mol | smiles = Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = ZBNZXTGUTAYRHI-UHFFFAOYSA-N }}Dasatinib, sold under the brand name Sprycel, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).[1] Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+).[1] It is taken by mouth.[1] Common side effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea.[1] Severe side effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome.[1] Use during pregnancy may result in harm to the baby.[1] It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.[1] Dasatinib was approved for medical use in the United States in 2006.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[2] In the United Kingdom, as of 2015, the medication costs the NHS about 2,505.00 pounds per month of treatment.[3] An Indian company has said they could make a generic version for 4 USD per dose.[4] Medical usesDasatinib is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive for the Philadelphia chromosome.[5] Adverse effectsNeutropenia and myelosuppression were common toxic effects. Fifteen people (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which was a suspected side effect of dasatinib. Some of these people required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of people developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in people treated with dasatinib.[6]On October 11, 2011 the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment. Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.[7] PharmacologyThe main targets of dasatinib are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other tyrosine kinases. History{{see also|Discovery and development of Bcr-Abl tyrosine kinase inhibitors}}Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd,[9] and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the medicinal chemists' underlying assumptions at a time when progress in the development of the molecule had stalled.[10] CostThe Union for Affordable Cancer Treatment objected to the price of dasatinib, in a letter to the U.S. trade representative. The average wholesale price in the U.S. is $367 per day, twice the price in other high income countries. The price in India, where the average annual per capita income is $1,570, and where most people pay out of pocket, is Rs6627 ($108) a day. Indian manufacturers offered to supply generic versions for $4 a day, but, under pressure from the U.S., the Indian Department of Industrial Policy and Promotion refused to issue a compulsory license.[4] Bristol-Myers Squibb justified the high prices of cancer drugs with the high R&D costs, but the Union of Affordable Cancer Treatment said that most of the R&D costs came from the U.S. government, including National Institutes of Health funded research and clinical trials, and a 50% tax credit. In England and Wales, the National Institute for Health and Care Excellence recommended against dasatinib because of the high cost-benefit ratio.[4] The Union for Affordable Cancer Treatment said that "the dasatinib dispute illustrates the shortcomings of US trade policy and its impact on cancer patients"[4] References1. ^1 2 3 4 5 6 7 {{cite web|title=Dasatinib|url=https://www.drugs.com/monograph/dasatinib.html|publisher=The American Society of Health-System Pharmacists|accessdate= 8 December 2017}} 2. ^{{cite web|title=WHO Model List of Essential Medicines (20th List)|url=http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1|work=World Health Organization|accessdate=29 June 2017|date=March 2017}} 3. ^{{cite book|title=British national formulary : BNF 69|date=2015|publisher=British Medical Association|isbn=9780857111562|page=614|edition=69}} 4. ^1 2 3 {{cite journal|last1=Cohen|first1=D|title=US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.|journal=BMJ (Clinical Research Ed.)|date=4 November 2014|volume=349|pages=g6593|pmid=25370846|doi=10.1136/bmj.g6593}} 5. ^{{cite journal|last1=Keating|first1=GM|title=Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.|journal=Drugs|date=January 2017|volume=77|issue=1|pages=85–96|doi=10.1007/s40265-016-0677-x|pmid=28032244}} 6. ^{{cite web|url=http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/|title=NHS - Healthcare News|author=|date=|website=nelm.nhs.uk}} 7. ^FDA: Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension, 10/11/2011. 8. ^{{Cite journal | last1 = Tokarski | first1 = J. S. | last2 = Newitt | first2 = J. A. | last3 = Chang | first3 = C. Y. | last4 = Cheng | first4 = J. D. | last5 = Wittekind | first5 = M. | last6 = Kiefer | first6 = S. E. | last7 = Kish | first7 = K. | last8 = Lee | first8 = F. Y. | last9 = Borzillerri | first9 = R. | last10 = Lombardo | first10 = L. J. | last11 = Xie | first11 = D. | last12 = Zhang | first12 = Y. | last13 = Klei | first13 = H. E. | title = The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants | doi = 10.1158/0008-5472.CAN-05-4187 | journal = Cancer Research | volume = 66 | issue = 11 | pages = 5790–5797 | year = 2006 | pmid = 16740718 | pmc = }} 9. ^https://www.otsuka.co.jp/en/company/release/2015/0302_01.html, http://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f, http://news.bms.com/press-release/financial-news/bristol-myers-squibb-announces-extension-us-agreement-abilify-and-estab 10. ^{{cite web|last1=Drahl|first1=Carmen|title=How Jagabandhu Das made dasatinib possible|url=http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/|website=The Safety Zone blog|publisher=Chemical & Engineering News|accessdate=29 August 2016|date=16 January 2012}} External links
13 : Alcohols|Amines|Anilides|Bristol-Myers Squibb|Otsuka Pharmaceutical|Chloroarenes|Non-receptor tyrosine kinase inhibitors|Orphan drugs|Piperazines|Pyrimidines|Thiazoles|World Health Organization essential medicines|RTT |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。